Trastuzumab (Herceptin):<\/strong>\n Trastuzumab is used in the treatment of breast cancer that \noverexpresses the HER2\/neu receptor. By blocking this receptor, it \ninhibits the growth of cancer cells and has become a standard therapy \nfor HER2-positive breast cancer.<\/p><\/li>Bevacizumab (Avastin):<\/strong>\n Bevacizumab is employed in various cancers, including colorectal, lung,\n and kidney cancer. It inhibits the formation of new blood vessels in \ntumors, depriving them of the nutrients they need to grow.<\/p><\/li>Pembrolizumab (Keytruda) and Nivolumab (Opdivo):<\/strong>\n These immune checkpoint inhibitors block PD-1, a protein on immune \ncells that prevents them from attacking cancer cells. They are used in \nseveral cancer types, such as melanoma, lung cancer, and kidney cancer, \nand have shown remarkable efficacy in some patients.<\/p><\/li>Ipilimumab (Yervoy):<\/strong>\n Ipilimumab targets CTLA-4, another immune checkpoint protein. It is \napproved for the treatment of advanced melanoma and has extended \nsurvival rates in some patients.<\/p><\/li><\/ol>These\n monoclonal antibodies represent a promising era in cancer therapy, \nshowcasing the potential of precision medicine. Their approval and \ncontinued development underscore their importance in improving the lives\n of cancer patients and advancing our understanding of this complex \ndisease.<\/p>
<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Advanced Bioinformatics
<\/span><\/h2><\/h2>\n\n
\n<\/p>
<\/span><\/p><\/p>
<\/p>
<\/p>
Welcome\n to our High-Tech Bioinformatics Subgroup! In 2024, our research \nendeavors are fueled by innovation and focused on cutting-edge \ntechnologies. We have identified three priority areas that drive our \nprojects and shape the future of bioinformatics.<\/p>
<\/p>
\n<\/p>
<\/span><\/p><\/p>
<\/p>
<\/p>
1) AI-based Bioinformatics:<\/strong>\n Artificial Intelligence (AI) is revolutionizing the field of \nbioinformatics. We\u2019re at the forefront of harnessing AI\u2019s power to \nanalyze biological data. By employing machine learning algorithms, we \ncan uncover hidden patterns, make predictions, and gain profound \ninsights into complex biological processes.<\/p>2) Single-Cell Analytic Study:<\/strong>\n Understanding biology at the single-cell level is crucial. Our research\n delves into single-cell analytics, a field that allows us to dissect \nand analyze individual cells with precision. This approach unveils \nintricate details of cellular behavior, aiding in disease understanding,\n drug development, and personalized medicine.<\/p><\/p>
\n<\/p>
<\/span><\/p><\/p>
<\/p>
<\/p>
3) Transferable AI Models:<\/strong>\n Collaboration and knowledge sharing are essential in today\u2019s scientific\n landscape. We\u2019re seeking individuals well-versed in building \ntransferable AI models. These models can be applied across various \nbiological datasets and domains, enhancing the efficiency and \neffectiveness of research.<\/p>Join us on \nthis exciting journey into the future of bioinformatics. Together, we\u2019ll\n push the boundaries of knowledge, advance scientific discovery, and \nmake a lasting impact on the world of biology.<\/p>
<\/p>
<\/p>\n\n\n\n\n\n\n\n\n\n
FDA Watch Subgroup<\/h2><\/h2>\n\n
<\/p>
<\/p>
<\/p>
The\n FDA Watch Subgroup keeps a close eye on the decisions made by the U.S. \nFood and Drug Administration (FDA) about which drugs get approved and \nwhich get withdrawn. They pay extra attention to drugs used in cancer \ntreatment, especially those that boost the immune system.<\/p>
If\n the FDA decides to take back its approval for a cancer drug, this \nsubgroup looks into why. They consider how this decision affects \npatients, doctors, and the drug companies, especially for specific types\n of cancer.<\/p>
They also stress the \nimportance of regularly checking if drugs are still safe and effective, \nespecially when it comes to the immune system and how drugs move through\n the body. They stay updated on new developments in cancer treatment, \nlike better ways to design drugs and target cancer cells, which could \nlead to improved treatments in the future.<\/p>\n\n\n\n\n\n\n\n
c-MET Discovery Subgroup<\/h3><\/h2>\n\n
The\n c-MET Discovery Subgroup focuses on studying a protein called c-MET, \nwhich is super important in cancer. They want to understand how c-MET \naffects how cancer cells resist treatments like targeted therapies and \nimmunotherapies. They\u2019ve found that c-MET plays a big role in making the\n tumor environment friendly to cancer cells by helping them hide from \nthe immune system.<\/p>
Their\n research shows that when c-MET is too active, it\u2019s linked to a protein \ncalled PD-L1, which cancer cells use to protect themselves from the \nimmune system. Also, c-MET seems to change some immune cells from \nfighting cancer to supporting it, and it helps create more immune cells \nthat suppress the immune response in the tumor.<\/p>
<\/p>
<\/p>\n
The\n subgroup is exploring exciting possibilities. They\u2019ve been looking at a\n special antibody called amivantamab, which can target two things: c-MET\n and EGFR. This antibody seems to help the immune system fight cancer \nbetter. This discovery opens doors to new treatments that use both c-MET\n blocking and immunotherapy, like a double attack against cancer growth \nand immune suppression.<\/p>
All\n in all, this subgroup\u2019s research is crucial. It helps us understand how\n c-MET works in cancer, giving hope for better treatments tailored to \neach patient. Their dedication to uncovering the mysteries of c-MET in \ncancer is vital for finding new ways to fight this disease.<\/p><\/div><\/div><\/div>
<\/p>\n\n\n\n\n\n\n\n<\/body>","protected":false},"excerpt":{"rendered":"","protected":false},"author":0,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"pagelayer_contact_templates":[],"_pagelayer_content":"","footnotes":""},"class_list":["post-21","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/cancerdiscovery.net\/open\/wp-json\/wp\/v2\/pages\/21","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cancerdiscovery.net\/open\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cancerdiscovery.net\/open\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/cancerdiscovery.net\/open\/wp-json\/wp\/v2\/comments?post=21"}],"version-history":[{"count":5,"href":"https:\/\/cancerdiscovery.net\/open\/wp-json\/wp\/v2\/pages\/21\/revisions"}],"predecessor-version":[{"id":863,"href":"https:\/\/cancerdiscovery.net\/open\/wp-json\/wp\/v2\/pages\/21\/revisions\/863"}],"wp:attachment":[{"href":"https:\/\/cancerdiscovery.net\/open\/wp-json\/wp\/v2\/media?parent=21"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}